Milliman Study: Medicare Advantage Costs 9% Less, Delivers $63B Annual Value
UnitedHealth Group released Milliman analyses showing Medicare Advantage plans cost the federal government 9% less than traditional Medicare—$1,117 versus $1,234 monthly—saving $1,400 annually per enrollee. The studies report MA’s managed-care model generated $63 billion in additional annual beneficiary value despite a 4% revenue reduction from the V28 risk model phase-in.
1. 2025 Headwinds and Stock Decline
UnitedHealth Group endured significant challenges in 2025 that depressed investor sentiment and led to a 34% drop in its share value. The company’s longtime chief executive unexpectedly departed, triggering executive uncertainty. A U.S. Senate investigation into aggressive Medicare Advantage billing practices further weighed on confidence, as internal documents indicated the use of financial incentives and AI-driven record searches to augment diagnosis coding. At the same time, UnitedHealth underestimated escalating care costs and higher utilization, driving quarterly earnings below consensus and exacerbating the year’s underperformance.
2. New Leadership and Operational Recovery Measures
Since taking the helm in May, CEO Steve Hemsley has spearheaded an independent assessment of core processes, concluding they are generally sound but in need of targeted enhancements. Management has exited underperforming benefit plans, repriced select networks, adjusted coverage levels and accelerated adoption of artificial-intelligence tools to streamline claims processing. These initiatives contributed to 12% revenue growth in the most recent quarter and supported an upward revision of full-year earnings guidance to $14.90 per share from $14.65, underscoring tangible progress in cost management and margin stabilization.
3. Long-Term Growth Outlook and Valuation Opportunity
UnitedHealth anticipates continued pressure from recent federal cuts to Medicare Advantage rates, yet projects solid earnings expansion in 2026 and targets sustainable double-digit earnings growth beginning in 2027. The company’s dual structure—combining UnitedHealthcare’s insurance scale with Optum’s data-driven services—creates a durable competitive moat. At approximately 17 times trailing earnings, valuation sits below multi-year averages, offering a potentially attractive entry point for investors with a multi-year horizon willing to navigate ongoing regulatory scrutiny.